Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Warning Sign:
Coherus Oncology has a Altman Z2-Score of -19.30, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Coherus Oncology's Altman Z2-Score or its related term are showing as below:
FRA:8C5'
s Altman Z2-Score Range Over the Past 10 Years
Min: -42.69 Med: -9.54 Max: 3.76
Current: -19.33
During the past 13 years, Coherus Oncology's highest Altman Z2-Score was 3.76. The lowest was -42.69. And the median was -9.54.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Coherus Oncology Altman Z2-Score Related Terms
Coherus Oncology Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: Altman Z2-Score Comparison
For the Biotechnology subindustry, Coherus Oncology's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Altman Z2-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Coherus Oncology's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.2715
+
3.26
*
-5.3428
+
6.72
*
-0.6109
+
1.05
*
0.4195
=
-19.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Coherus Oncology (FRA:8C5) has a Altman Z2-Score of -19.30 as of Jul. 03, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #1050 out of 1394 companies in the Biotechnology industry, placing it in the top 75.3%.
Is Coherus Oncology's Altman Z2-Score too high?
Coherus Oncology's current Altman Z2-Score is -19.30. Based on the distribution chart, Coherus Oncology ranks #1050 out of 1394 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Altman Z2-Score compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #1050 out of 1394 companies for Altman Z2-Score. This places Coherus Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Altman Z2-Score is -19.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.66, compared to a current price of €1.25 — trading 88.6% above its estimated fair value. The current Altman Z2-Score is -19.30. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Altman Z2-Score is -19.30 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.25 is trading 88.6% above its estimated GF Value™ of €0.66.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Altman Z2-Score: -19.30
GF Value™: €0.66 vs. price of €1.25 (88.6% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score
Get the complete analysis for FRA:8C5
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
